The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Macro EconomyMediumUpdated×2•Originally published 19 April 2026•Updated 20 April 2026•

1 min read

Trump Directs FDA to Fast-Track Medical Psychedelics Review

Emmanuel Macron's face centered between cracked Visa and Mastercard cards, with Euro and Ethereum symbols, bank buildings, and digital payment cards.

Key Facts

1President Trump directed an accelerated FDA review of psychedelics like ibogaine following a text exchange with Joe Rogan.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Expanded the scope to include 'Right to Try' access and potential spillover effects on cannabis reform, while clarifying that the legal status of the substances remains unchanged.

Version 1about 1 month ago

What changed: The story was updated to reflect that the directives have been formalized through an official executive order.

President Donald Trump has formalized an executive order to accelerate the FDA regulatory pathway for psychedelic substances like ibogaine for medical use. The order specifically includes fast-tracking 'Right to Try' access for compounds such as psilocybin and MDMA, aimed at aiding patients with treatment-resistant conditions. While the directive focuses on research and clinical trials, it does not alter the current legal status of these substances. Experts suggest this federal shift could unlock stalled cannabis reforms by establishing a robust, evidence-based medical framework. Analysts view the move as a significant bullish signal for the biotech sector, potentially leading to faster market entries. Consequently, market sentiment remains positive for specialized firms including CMPS, ATAI, and MNMD.